{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:28:40Z","timestamp":1790832520219,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":730,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000023","name":"Government of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000023","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000082","name":"Cystic Fibrosis Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000082","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.jcf.2020.07.015","type":"journal-article","created":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T08:15:37Z","timestamp":1596096937000},"page":"106-119","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Emerging preclinical modulators developed for F508del-CFTR have the potential to be effective for ORKAMBI resistant processing mutants"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0237-4079","authenticated-orcid":false,"given":"Onofrio","family":"Laselva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alec","family":"Popa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarini N.A.","family":"Gunawardena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Gonska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo J.","family":"Moraes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7063-3418","authenticated-orcid":false,"given":"Christine E.","family":"Bear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"46","key":"10.1016\/j.jcf.2020.07.015_bib0001","doi-asserted-by":"crossref","first-page":"18843","DOI":"10.1073\/pnas.1105787108","article-title":"Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809","volume":"108","author":"Van Goor","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"44","key":"10.1016\/j.jcf.2020.07.015_bib0002","doi-asserted-by":"crossref","first-page":"18825","DOI":"10.1073\/pnas.0904709106","article-title":"Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770","volume":"106","author":"Van Goor","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.jcf.2020.07.015_bib0003","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jcf.2020.07.015_bib0004","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jcf.2018.05.016","article-title":"Rescue of CFTR NBD2 mutants N1303K and S1235R is influenced by the functioning of the autophagosome","volume":"17","author":"Liu","year":"2018","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.jcf.2020.07.015_bib0005","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jcf.2018.05.011","article-title":"Physiological and pharmacological characterization of the N1303K mutant CFTR","volume":"17","author":"DeStefano","year":"2018","journal-title":"J Cyst Fibros"},{"issue":"14","key":"10.1016\/j.jcf.2020.07.015_bib0006","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.121159","article-title":"Residual function of cystic fibrosis mutants predicts response to small molecule CFTR modulators","volume":"3","author":"Han","year":"2018","journal-title":"JCI Insight"},{"issue":"2","key":"10.1016\/j.jcf.2020.07.015_bib0007","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ebiom.2014.12.005","article-title":"Measurements of functional responses in human primary lung cells as a basis for personalized therapy for cystic fibrosis","volume":"2","author":"Awatade","year":"2015","journal-title":"EBioMedicine"},{"issue":"11","key":"10.1016\/j.jcf.2020.07.015_bib0008","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1038\/s41591-018-0200-x","article-title":"Structure-guided combination therapy to potently improve the function of mutant CFTRs","volume":"24","author":"Veit","year":"2018","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.jcf.2020.07.015_bib0009","doi-asserted-by":"crossref","first-page":"7375","DOI":"10.1038\/s41598-017-07504-1","article-title":"Correction of CFTR function in nasal epithelial cells from cystic fibrosis patients predicts improvement of respiratory function by CFTR modulators","volume":"7","author":"Pranke","year":"2017","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.jcf.2020.07.015_bib0010","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1159\/000475578","article-title":"Combination of Correctors Rescues CFTR Transmembrane-Domain Mutants by Mitigating their Interactions with Proteostasis","volume":"41","author":"Lopes-Pacheco","year":"2017","journal-title":"Cell Physiol Biochem"},{"issue":"3","key":"10.1016\/j.jcf.2020.07.015_bib0011","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1091\/mbc.e14-04-0935","article-title":"From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations","volume":"27","author":"Veit","year":"2016","journal-title":"Mol Biol Cell"},{"issue":"11","key":"10.1016\/j.jcf.2020.07.015_bib0012","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1016\/j.drudis.2019.05.029","article-title":"Pharmacological analysis of CFTR variants of cystic fibrosis using stem cell-derived organoids","volume":"24","author":"Chen","year":"2019","journal-title":"Drug Discov Today"},{"issue":"1","key":"10.1016\/j.jcf.2020.07.015_bib0013","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.201800172","article-title":"Folding-function relationship of the most common cystic fibrosis-causing CFTR conductance mutants","volume":"2","author":"van Willigen","year":"2019","journal-title":"Life Sci Alliance"},{"issue":"7","key":"10.1016\/j.jcf.2020.07.015_bib0014","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/nchembio.1253","article-title":"Mechanism-based corrector combination restores DeltaF508-CFTR folding and function","volume":"9","author":"Okiyoneda","year":"2013","journal-title":"Nat Chem Biol"},{"issue":"6","key":"10.1016\/j.jcf.2020.07.015_bib0015","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1124\/mol.118.111799","article-title":"Correctors of the Major Cystic Fibrosis Mutant Interact through Membrane-Spanning Domains","volume":"93","author":"Laselva","year":"2018","journal-title":"Mol Pharmacol"},{"issue":"1","key":"10.1016\/j.jcf.2020.07.015_bib0016","doi-asserted-by":"crossref","first-page":"11404","DOI":"10.1038\/s41598-018-29276-y","article-title":"A novel triple combination of pharmacological chaperones improves F508del-CFTR correction","volume":"8","author":"Carlile","year":"2018","journal-title":"Sci Rep"},{"issue":"17","key":"10.1016\/j.jcf.2020.07.015_bib0017","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","article-title":"VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles","volume":"379","author":"Keating","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2020.07.015_bib0018","first-page":"1","article-title":"The preclinical discovery and development of the combination of ivacaftor + tezacaftor used to treat cystic fibrosis","author":"Guerra","year":"2020","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.jcf.2020.07.015_bib0019","article-title":"Functional rescue of c.3846G>A (W1282X) in patient-derived nasal cultures achieved by inhibition of nonsense mediated decay and protein modulators with complementary mechanisms of action","author":"Laselva","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2020.07.015_bib0020","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.bcp.2016.09.005","article-title":"The investigational Cystic Fibrosis drug Trimethylangelicin directly modulates CFTR by stabilizing the first membrane-spanning domain","volume":"119","author":"Laselva","year":"2016","journal-title":"Biochem Pharmacol"},{"issue":"10","key":"10.1016\/j.jcf.2020.07.015_bib0021","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1177\/1087057115605834","article-title":"Facilitating structure-function studies of cftr modulator sites with efficiencies in mutagenesis and functional screening","volume":"20","author":"Molinski","year":"2015","journal-title":"J Biomol Screen"},{"issue":"1","key":"10.1016\/j.jcf.2020.07.015_bib0022","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1165\/ajrcmb.10.1.7507342","article-title":"CFTR expression and chloride secretion in polarized immortal human bronchial epithelial cells","volume":"10","author":"Cozens","year":"1994","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"4","key":"10.1016\/j.jcf.2020.07.015_bib0023","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.jcf.2018.12.001","article-title":"Isogenic cell models of cystic fibrosis-causing variants in natively expressing pulmonary epithelial cells","volume":"18","author":"Valley","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2020.07.015_bib0024","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1089\/hum.2017.201","article-title":"Transducing airway basal cells with a helper-dependent adenoviral vector for lung gene therapy","volume":"29","author":"Cao","year":"2018","journal-title":"Hum Gene Ther"},{"issue":"9","key":"10.1016\/j.jcf.2020.07.015_bib0025","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.15252\/emmm.201607137","article-title":"Orkambi(R) and amplifier co-therapy improves function from a rare CFTR mutation in gene-edited cells and patient tissue","volume":"9","author":"Molinski","year":"2017","journal-title":"EMBO Mol Med"},{"issue":"1","key":"10.1016\/j.jcf.2020.07.015_bib0026","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jcf.2018.03.013","article-title":"The CF Canada-sick kids program in individual CF therapy: a resource for the advancement of personalized medicine in CF","volume":"18","author":"Eckford","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.jcf.2020.07.015_bib0027","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1124\/mol.119.117143","article-title":"ORKAMBI-mediated rescue of mucociliary clearance in cystic fibrosis primary respiratory cultures is enhanced by arginine uptake, arginase inhibition, and promotion of nitric oxide signaling to the cystic fibrosis transmembrane conductance regulator channel","volume":"96","author":"Wu","year":"2019","journal-title":"Mol Pharmacol"},{"issue":"2","key":"10.1016\/j.jcf.2020.07.015_bib0028","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1124\/mol.118.112177","article-title":"Lipophilicity of the cystic fibrosis drug, ivacaftor (VX-770), and its destabilizing effect on the major CF-causing mutation: f508del","volume":"94","author":"Chin","year":"2018","journal-title":"Mol Pharmacol"},{"issue":"1","key":"10.1016\/j.jcf.2020.07.015_bib0029","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/bs.pmch.2018.01.001","article-title":"Recent progress in the discovery and development of small-molecule modulators of CFTR","volume":"57","author":"Kym","year":"2018","journal-title":"Prog Med Chem"},{"issue":"11","key":"10.1016\/j.jcf.2020.07.015_bib0030","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1021\/acsmedchemlett.9b00377","article-title":"Discovery of ABBV\/GLPG-3221, a potent corrector of CFTR for the treatment of cystic fibrosis","volume":"10","author":"Scanio","year":"2019","journal-title":"ACS Med Chem Lett"},{"issue":"11","key":"10.1016\/j.jcf.2020.07.015_bib0031","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1021\/acs.oprd.9b00292","article-title":"Development of an Enantioselective [3\u00a0+\u00a02] Cycloaddition To Synthesize the Pyrrolidine Core of ABBV-3221 on Multikilogram Scale","volume":"23","author":"Hartung","year":"2019","journal-title":"Org Process Res Dev"},{"key":"10.1016\/j.jcf.2020.07.015_bib0032","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.3389\/fphar.2018.01221","article-title":"Identification and characterization of novel CFTR potentiators","volume":"9","author":"Gees","year":"2018","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1016\/j.jcf.2020.07.015_bib0033","doi-asserted-by":"crossref","DOI":"10.3390\/biom10020334","article-title":"Anti-infectives restore ORKAMBI((R)) rescue of F508del-CFTR function in human bronchial epithelial cells infected with clinical strains of P. aeruginosa","volume":"10","author":"Laselva","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.jcf.2020.07.015_bib0034","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.omtm.2020.05.002","article-title":"Allele-specific prevention of nonsense-mediated decay in cystic fibrosis using homology-independent genome editing","volume":"17","author":"Erwood","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"8","key":"10.1016\/j.jcf.2020.07.015_bib0035","doi-asserted-by":"crossref","DOI":"10.3390\/cells8080804","article-title":"Cholesterol interaction directly enhances intrinsic activity of the cystic fibrosis transmembrane conductance regulator (CFTR)","volume":"8","author":"Chin","year":"2019","journal-title":"Cells"},{"issue":"10","key":"10.1016\/j.jcf.2020.07.015_bib0036","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1096\/fba.2019-00039","article-title":"Activity of lumacaftor is not conserved in zebrafish Cftr bearing the major cystic fibrosis-causing mutation","volume":"1","author":"Laselva","year":"2019","journal-title":"FASEB Bioadv"},{"issue":"2","key":"10.1016\/j.jcf.2020.07.015_bib0037","doi-asserted-by":"crossref","DOI":"10.3390\/jpm10020040","article-title":"The CFTR Mutation c.3453 G >C (D1152H) confers an anion selectivity defect in primary airway tissue that can be rescued by Ivacaftor","volume":"10","author":"Laselva","year":"2020","journal-title":"J Pers Med"},{"key":"10.1016\/j.jcf.2020.07.015_bib0038","doi-asserted-by":"crossref","first-page":"719","DOI":"10.3389\/fphar.2018.00719","article-title":"Molecular mechanism of action of trimethylangelicin derivatives as CFTR modulators","volume":"9","author":"Laselva","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jcf.2020.07.015_bib0039","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00205-2020","article-title":"A helper-dependent adenoviral vector rescues CFTR to wild type functional levels in CF epithelial cells harbouring class I mutations","author":"Cao","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2020.07.015_bib0040","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3389\/fphar.2019.00514","article-title":"Identification of GLPG\/ABBV-2737, a novel class of corrector, which exerts functional synergy with other CFTR modulators","volume":"10","author":"de Wilde","year":"2019","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.jcf.2020.07.015_bib0041","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1165\/ajrcmb.23.3.4060","article-title":"Role of K(V)LQT1 in cyclic adenosine monophosphate-mediated Cl(-) secretion in human airway epithelia","volume":"23","author":"Mall","year":"2000","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"7","key":"10.1016\/j.jcf.2020.07.015_bib0042","doi-asserted-by":"crossref","first-page":"L593","DOI":"10.1152\/ajplung.00321.2015","article-title":"Generation and functional characterization of epithelial cells with stable expression of SLC26A9 Cl- channels","volume":"310","author":"Salomon","year":"2016","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.jcf.2020.07.015_bib0043","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.coph.2017.10.002","article-title":"Bypassing CFTR dysfunction in cystic fibrosis with alternative pathways for anion transport","volume":"34","author":"Li","year":"2017","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.jcf.2020.07.015_bib0044","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.3389\/fphar.2018.01112","article-title":"Role of the SLC26A9 chloride channel as disease modifier and potential therapeutic target in cystic fibrosis","volume":"9","author":"Balazs","year":"2018","journal-title":"Front Pharmacol"},{"issue":"10","key":"10.1016\/j.jcf.2020.07.015_bib0045","doi-asserted-by":"crossref","first-page":"C943","DOI":"10.1152\/ajpcell.00030.2014","article-title":"N-glycosylation and topology of the human SLC26 family of anion transport membrane proteins","volume":"306","author":"Li","year":"2014","journal-title":"Am J Physiol Cell Physiol"},{"issue":"6","key":"10.1016\/j.jcf.2020.07.015_bib0046","doi-asserted-by":"crossref","first-page":"L912","DOI":"10.1152\/ajplung.00178.2016","article-title":"The CFTR trafficking mutation F508del inhibits the constitutive activity of SLC26A9","volume":"312","author":"Bertrand","year":"2017","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"2","key":"10.1016\/j.jcf.2020.07.015_bib0047","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1085\/jgp.200409059","article-title":"Discovery of glycine hydrazide pore-occluding CFTR inhibitors: mechanism, structure-activity analysis, and in vivo efficacy","volume":"124","author":"Muanprasat","year":"2004","journal-title":"J Gen Physiol"},{"issue":"6","key":"10.1016\/j.jcf.2020.07.015_bib0048","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1002\/jcp.22967","article-title":"Differential contribution of SLC26A9 to Cl(-) conductance in polarized and non-polarized epithelial cells","volume":"227","author":"Ousingsawat","year":"2012","journal-title":"J Cell Physiol"},{"issue":"6389","key":"10.1016\/j.jcf.2020.07.015_bib0049","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/358761a0","article-title":"Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive","volume":"358","author":"Denning","year":"1992","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.jcf.2020.07.015_bib0050","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.bbrc.2007.12.065","article-title":"Low temperature induces the delivery of mature and immature CFTR to the plasma membrane","volume":"366","author":"Rennolds","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"10.1016\/j.jcf.2020.07.015_bib0051","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0119796","article-title":"Rescue of NBD2 mutants N1303K and S1235R of CFTR by small-molecule correctors and transcomplementation","volume":"10","author":"Rapino","year":"2015","journal-title":"PLoS ONE"},{"issue":"4","key":"10.1016\/j.jcf.2020.07.015_bib0052","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1039\/b924455g","article-title":"CFTR chloride channel in the apical compartments: spatiotemporal coupling to its interacting partners","volume":"2","author":"Li","year":"2010","journal-title":"Integr Biol (Camb)"},{"issue":"6","key":"10.1016\/j.jcf.2020.07.015_bib0053","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1242\/jcs.177907","article-title":"Correctors of mutant CFTR enhance subcortical cAMP-PKA signaling through modulating ezrin phosphorylation and cytoskeleton organization","volume":"129","author":"Abbattiscianni","year":"2016","journal-title":"J Cell Sci"},{"issue":"13","key":"10.1016\/j.jcf.2020.07.015_bib0054","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1242\/jcs.185629","article-title":"EPAC1 activation by cAMP stabilizes CFTR at the membrane by promoting its interaction with NHERF1","volume":"129","author":"Lobo","year":"2016","journal-title":"J Cell Sci"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199320308079?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199320308079?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:44:17Z","timestamp":1761601457000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199320308079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S1569199320308079"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2020.07.015","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging preclinical modulators developed for F508del-CFTR have the potential to be effective for ORKAMBI resistant processing mutants","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2020.07.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}